Quick Answer
Estrella Immunopharma, Inc. reported Diluted EPS of $0.35 per share (loss) for fiscal year 2025.
Estrella Immunopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.35 | -29.6% |
| 2024 | -$0.27 | +99.3% |
| 2023 | -$36.35 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | -44.4% | +13.3% |
| June 30, 2025 | -$0.15 | -36.4% | -150.0% |
| March 31, 2025 | -$0.06 | -500.0% | +33.3% |
| September 30, 2024 | -$0.09 | +94.9% | +18.2% |
| June 30, 2024 | -$0.11 | — | -1000.0% |
| March 31, 2024 | -$0.01 | +99.9% | +66.7% |
| December 31, 2023 | -$0.03 | +99.8% | +98.3% |
| September 30, 2023 | -$1.78 | +94.8% | +78.1% |
- Estrella Immunopharma, Inc. showed a decrease of -29.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Estrella Immunopharma, Inc.’s diluted eps has grown by 99.0% (from $36.35 per share (loss) to $0.35 per share (loss)).
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: